Sometimes investors have to hold their noses a bit to take advantage of mispricings in the market. Abbott Labs (NYSE:ABT) is a good case in point; the company has changed its reporting by classifying its businesses into three meaningless categories, it makes rampant use of "one-time" charges, and the growth profile is heavily overweight to a small number of products.

TUTORIAL: Investing Concepts

Still, cash flow is cash flow, and Abbott produces quite a lot of it, even though the Street does not seem all too willing to value it as highly as the cash flow from other medical technology names. (For more, see 5 Stocks With Solid Cash Flow.)

After Some Digging, a Solid Quarter
Abbott's first quarter results require a little digging and reinterpretation, but the numbers ultimately look pretty good. Reported revenue was up more than 17%, while organic revenue growth was more on the order of 5% to 6%. Growth was led again by the pharmaceutical business, which grew 24% this quarter. Vascular posted a decent result as well (up 13%), while diagnostics and nutrition both contributed high single-digit growth.

Likewise, the profitability side of the ledger was a bit murky, but the underlying results are solid. Gross profit improved more than a point from a year ago and would have been even better if not for the impact of foreign currency on the results. Moving along, Abbott continued its roughly eight-year tradition of "one time" items in the income statement, but operating income still grew around 13%. Stripping everything out and looking at a decidedly "home brew" organic EPS, Abbott's bottom line profitability increased at about the same rate as its organic sales - that is, mid-single-digits.

Unbalanced Growth Could Be an Issue Later
Excluding the impact of the acquisitions of Solvay and Piramal, it is clear that a large percentage (roughly three-quarters) of Abbott's growth is coming from just two products - Humira and drug-coated stents. Both are still growing well; Humira was up 18% worldwide, and stents were up 15%, but both have upcoming challengers.

Humira's growth could be compromised by the eventual launch of oral JAK3 drugs (including one from Pfizer (NYSE:PFE), while the drug-coated stent business should see new launches from Boston Scientific (NYSE:BSX), Johnson & Johnson (NYSE:JNJ) and Medtronic (NYSE:MDT) in the near future.

The bear scenario will see those new products chip away at these growth drivers and stall out Abbott's growth almost entirely. On the flipside, the JAK3 data is not quite living up to all of its hype, and Abbott is pushing for expanded labeling on Humira. Similarly, the drug-coated stent may not be quite as vulnerable as the skeptics think, as Abbott does have its own pipeline of products as well.

Noise and a Lumpy Pipeline
As previously mentioned, Abbott has chosen to recategorize its reporting into three all but meaningless segments. Instead of straightforward categories like "pharmaceuticals", investors will now be treated to "durable growth", "proprietary pharmaceuticals" and "innovation-driven devices". Though I do not want to make too much of this, this is the sort of silly hand-waving that sometimes unnerves me when it comes to evaluating a management team. At least it looks as though investors will still be able to reconstruct the old categories, and the release of more data on the company's emerging markets exposure is welcome.

Elsewhere, the company's pipeline is looking a bit lumpy. There are compounds in the hopper for cancer and Hep C in 2014, but not a lot in the meantime. Perhaps that makes Abbott a candidate for a little more shopping or in-licensing, though management may feel that the introduction of a Parkinson's drug in 2012 and an endometriosis drug in 2013, partnered with Neurocrine Biosciences (Nasdaq:NBIX), is sufficient, assuming both get approval.

The Bottom Line
Abbott shares may suffer a bit if more, investors believe that Johnson & Johnson has turned a corner. That said, JNJ looks more like a false dawn than a turnaround, and Abbott seems to have a pretty compelling long-term valuation today. It is impossible to excuse all of management's questionable moves, but investors willing to put up with a little noise may have a real bargain here. (For more, see Pharmaceutical Phenoms: America's Best-Selling Medicines.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  2. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
  3. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  4. Stock Analysis

    Analyzing Dish Network's Return on Equity (ROE) (DISH, TWC)

    Analyze Dish Network's return on equity (ROE), understand why it has vacillated so greatly in recent years and learn what factors are influencing it.
  5. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  6. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  7. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  8. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  9. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  10. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center